The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial von Gibson, C. Michael, Halaby, Rim, Korjian, Serge, Daaboul, Yazan, Arbetter, Douglas F, Yee, Megan K, Goldhaber, Samuel Z, Hull, Russel, Hernandez, Adrian F, Gold, Alex, Wiens, Brian, Leeds, Janet, Harrington, Robert A, Cohen, Alexander T

Volltext

Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy von Arbetter, Douglas F., Jain, Purva, Yee, Megan K., Michalak, Nathan, Hernandez, Adrian F., Hull, Russell D., Goldhaber, Samuel Z., Harrington, Robert A., Gold, Alex, Cohen, Alexander T., Gibson, C. Michael

Volltext

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial von Hobbs, F. D. Richard, Montgomery, Hugh, Padilla, Francisco, Simón-Campos, Jesus Abraham, Arbetter, Douglas, Seegobin, Seth, Kiazand, Alexandre, Streicher, Katie, Martinez-Alier, Nuria, Cohen, Taylor S., Esser, Mark T.

Volltext

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial von Hobbs, F. D. Richard, Montgomery, Hugh, Padilla, Francisco, Simón-Campos, Jesus Abraham, Kim, Kenneth, Arbetter, Douglas, Padilla, Kelly W., Reddy, Venkatesh Pilla, Seegobin, Seth, Streicher, Katie, Templeton, Alison, Viani, Rolando M., Johnsson, Eva, Koh, Gavin C. K. W., Esser, Mark T.

Volltext

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial) von Kijak, Gustavo H., Ahani, Bahar, Arbetter, Douglas, Chuecos, Fernando, Gopalakrishnan, Vancheswaran, Beloor, Jagadish, Brady, Tyler, Nguyen, Amy, Roe, Tiffany L., Schuko, Nicolette, Zhang, Tianhui, Hobbs, F. D. Richard, Padilla, Francisco, Kelly, Elizabeth J., Montgomery, Hugh, Streicher, Katie

Volltext

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study von Richard Hobbs, F D, Montgomery, Hugh, Padilla, Francisco, Campos, Jesus Abraham Simón, Arbetter, Douglas, Seegobin, Seth, Kiazand, Alexandre, Streicher, Katie, Martinez-Alier, Nuria, Cohen, Taylor, Esser, Mark T

Volltext

1918. Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial von Campos, Jesus Abraham Simón, Arbetter, Douglas, Montgomery, Hugh, Richard Hobbs, F D, Padilla, Francisco, Kim, Kenneth, Streicher, Katie, Templeton, Alison, Viani, Rolando M, Esser, Mark T

Volltext

1924. Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Tri... von Richard Hobbs, F D, Montgomery, Hugh, Padilla, Francisco, Kim, Kenneth, Simón Campos, Jesus Abraham, Arbetter, Douglas, Padilla, Kelly W, Reddy, Venkatesh P, Seegobin, Seth, Streicher, Katie, Viani, Rolando M, Koh, Gavin C KW, Esser, Mark T

Volltext

1160. Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVI... von Kijak, Gustavo H, Ahani, Bahar, Arbetter, Douglas, Brady, Tyler, Chuecos, Fernando, Gopalakrishnan, Vancheswaran, Roe, Tiffany L, Schuko, Nicolette, Richard Hobbs, F D, Padilla, Francisco, Kelly, Elizabeth J, Montgomery, Hugh, Streicher, Katie

Volltext

Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy von Gibson, C. Michael, Korjian, Serge, Chi, Gerald, Daaboul, Yazan, Jain, Purva, Arbetter, Douglas, Goldhaber, Samuel Z., Hull, Russel, Hernandez, Adrian F., Lopes, Renato D., Gold, Alex, Cohen, Alexander T., Harrington, Robert A.

Volltext

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy von Gibson, C. Michael, Korjian, Serge, Chi, Gerald, Daaboul, Yazan, Jain, Purva, Arbetter, Douglas, Goldhaber, Samuel Z, Hull, Russel, Hernandez, Adrian F, Lopes, Renato D, Gold, Alex, Cohen, Alexander T, Harrington, Robert A, Bello, F, Ferrari, A.E, Jure, H, Macin, S, Oliva, M, Parody, M, Poy, C, Baker, R, Coughlin, P, Finfer, S, Rubinfeld, A, Huber, K, Konig, J, Mathies, R, Schoenerr, H, Adzerikho, I, Koryk, V, Mikhailova, E, Mitkovskaya, N, Pimanov, S, Polonetsy, L, Soroka, N, Blockmans, D, Delforge, M, Dive, A, Lienart, F, Bizzacchi, J. Annichino, Fiss, E, Freire, A, Manenti, E, Ramacciotti, E, Raymuno, S, Rocha, A, Dimov, B, Grigorov, M, Kalpachki, R, Kamenova, Z, Kostadinova, M, Milanova, M, Pencheva, G, Runev, N, Stoeva, N, Stoyanov, M, Syulemzova, S, Todorov, G, Tokmakova, M, Dhar, A, Douketis, J, Le Gal, G, Pearce, M, Provencher, S, Verreault, S, Alarcon, M. Arias, Lazcano, M. Opazo, Cardenas, S. Potthoff, Butkovic-Soldo, S, Car, S, Ciglenecki, N, Francetic, I, Jakopovic, M, Kalinic-Grgorinic, H, Knezevic, A, Marusic, S, Vagic, J. Sikic, Skerk, V, Cermak, O, Chlumsky, J, Chochola, J, Cizek, V, Dunaj, M, Dusek, J, Francek, L, Havelka, J, Herold, M, Holaj, R, Horny, I, Hubac, J, Jajtner, P, Kolman, P, Lang, P, Mikulova, J, Podpera, I, Reiterer, P, Spacek, R, Vejvoda, J, Vyhnanek, M, Christensen, H

Volltext

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial) von Kijak, Gustavo H, Ahani, Bahar, Arbetter, Douglas, Chuecos, Fernando, Gopalakrishnan, Vancheswaran, Beloor, Jagadish, Brady, Tyler, Nguyen, Amy, Roe, Tiffany L, Schuko, Nicolette, Zhang, Tianhui, Hobbs, FD Richard, Padilla, Francisco, Kelly, Elizabeth J, Montgomery, Hugh, Streicher, Katie

Volltext bestellen

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial von Hobbs, FD Richard, Montgomery, Hugh, Padilla, Francisco, Simón-Campos, Jesus Abraham, Kim, Kenneth, Arbetter, Douglas, Padilla, Kelly W, Reddy, Venkatesh Pilla, Seegobin, Seth, Streicher, Katie, Templeton, Alison, Viani, Rolando M, Johnsson, Eva, Koh, Gavin CKW, Esser, Mark T

Volltext bestellen

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-cont... von Montgomery, Hugh, Hobbs, FD Richard, Padilla, Francisco, Arbetter, Douglas, Templeton, Alison, Seegobin, Seth, Kim, Kenneth, Campos, Jesus Abraham Simón, Arends, Rosalinda H, Brodek, Bryan H, Brooks, Dennis, Garbes, Pedro, Jimenez, Julieta, Koh, Gavin CKW, Padilla, Kelly W, Streicher, Katie, Viani, Rolando M, Alagappan, Vijay, Pangalos, Menelas N, Esser, Mark T, TACKLE study group

Volltext bestellen

Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy von Gibson, C. Michael, Korjian, Serge, Chi, Gerald, Daaboul, Yazan, Jain, Purva, Arbetter, Douglas, Goldhaber, Samuel Z, Hull, Russel, Hernandez, Adrian F, Lopes, Renato D, Gold, Alex, Cohen, Alexander T, Harrington, Robert A

Volltext bestellen